191 related articles for article (PubMed ID: 34057677)
1. Effect of a Patient Support Program for Idiopathic Pulmonary Fibrosis Patients on Medication Persistence: A Retrospective Database Analysis.
Near AM; Burudpakdee C; Viswanathan S; Kaila S
Adv Ther; 2021 Jul; 38(7):3888-3899. PubMed ID: 34057677
[TBL] [Abstract][Full Text] [Related]
2. Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study.
Corral M; DeYoung K; Kong AM
BMC Pulm Med; 2020 Jul; 20(1):188. PubMed ID: 32652979
[TBL] [Abstract][Full Text] [Related]
3. Impact of timing of nintedanib initiation among patients newly diagnosed with idiopathic pulmonary fibrosis.
Singer D; Bengtson LGS; Conoscenti CS; Anderson AJ; Brekke L; Shetty SS; de Andrade J
J Med Econ; 2022; 25(1):532-540. PubMed ID: 35321616
[TBL] [Abstract][Full Text] [Related]
4. Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study.
Huang TH; Kuo CW; Chen CW; Tseng YL; Wu CL; Lin SH
BMC Pulm Med; 2021 May; 21(1):165. PubMed ID: 33992083
[TBL] [Abstract][Full Text] [Related]
5. Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment.
Noor S; Nawaz S; Chaudhuri N
Adv Ther; 2021 Jan; 38(1):268-277. PubMed ID: 33098554
[TBL] [Abstract][Full Text] [Related]
6. Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis.
Bonella F; Kreuter M; Hagmeyer L; Neurohr C; Keller C; Kohlhaeufl MJ; Müller-Quernheim J; Milger K; Prasse A;
Respiration; 2016; 92(2):98-106. PubMed ID: 27544537
[TBL] [Abstract][Full Text] [Related]
7. Clinical Significance of Continuable Treatment with Nintedanib Over 12 Months for Idiopathic Pulmonary Fibrosis in a Real-World Setting.
Kato M; Sasaki S; Tateyama M; Arai Y; Motomura H; Sumiyoshi I; Ochi Y; Watanabe J; Ihara H; Togo S; Takahashi K
Drug Des Devel Ther; 2021; 15():223-230. PubMed ID: 33500614
[TBL] [Abstract][Full Text] [Related]
8. The Gender-Age-Physiology system as a prognostic model in patients with idiopathic pulmonary fibrosis treated with nintedanib: a longitudinal cohort study.
Abe M; Tsushima K; Yoshioka K; Sakayori M; Suzuki K; Hirasawa Y; Kawasaki T; Ikari J; Terada J; Tatsumi K
Adv Respir Med; 2020; 88(5):369-376. PubMed ID: 33169806
[TBL] [Abstract][Full Text] [Related]
9. Adoption of the Antifibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary Fibrosis.
Dempsey TM; Payne S; Sangaralingham L; Yao X; Shah ND; Limper AH
Ann Am Thorac Soc; 2021 Jul; 18(7):1121-1128. PubMed ID: 33465323
[No Abstract] [Full Text] [Related]
10. Antifibrotic therapies reduce mortality and hospitalization among Medicare beneficiaries with idiopathic pulmonary fibrosis.
Mooney J; Reddy SR; Chang E; Broder MS; Gokhale S; Corral M
J Manag Care Spec Pharm; 2021 Dec; 27(12):1724-1733. PubMed ID: 34818092
[No Abstract] [Full Text] [Related]
11. Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan.
Ogura T; Inoue Y; Azuma A; Homma S; Kondoh Y; Tanaka K; Ochiai K; Sugiyama Y; Nukiwa T
Adv Ther; 2023 Apr; 40(4):1474-1493. PubMed ID: 36692681
[TBL] [Abstract][Full Text] [Related]
12. Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS® trials.
Costabel U; Behr J; Crestani B; Stansen W; Schlenker-Herceg R; Stowasser S; Raghu G
Respir Res; 2018 Sep; 19(1):167. PubMed ID: 30176872
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.
Crestani B; Huggins JT; Kaye M; Costabel U; Glaspole I; Ogura T; Song JW; Stansen W; Quaresma M; Stowasser S; Kreuter M
Lancet Respir Med; 2019 Jan; 7(1):60-68. PubMed ID: 30224318
[TBL] [Abstract][Full Text] [Related]
14. Using group based trajectory modeling for assessing medication adherence to nintedanib among idiopathic pulmonary fibrosis patients.
Nili M; Epstein AJ; Nunag D; Olson A; Borah B
BMC Pulm Med; 2023 Jun; 23(1):230. PubMed ID: 37370093
[TBL] [Abstract][Full Text] [Related]
15. A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis.
Harari S; Caminati A; Poletti V; Confalonieri M; Gasparini S; Lacedonia D; Luppi F; Pesci A; Sebastiani A; Spagnolo P; Vancheri C; Balestro E; Bonifazi M; Cerri S; De Giacomi F; Della Porta R; Foschino Barbaro MP; Fui A; Pasquinelli P; Rosso R; Tomassetti S; Specchia C; Rottoli P;
Respiration; 2018; 95(6):433-440. PubMed ID: 29587263
[TBL] [Abstract][Full Text] [Related]
16. Association between nintedanib adherence trajectory and healthcare use among idiopathic pulmonary fibrosis patients.
Nili M; Epstein AJ; Nunag D; Olson A; Borah BJ
BMC Pulm Med; 2024 Mar; 24(1):141. PubMed ID: 38504247
[TBL] [Abstract][Full Text] [Related]
17. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
[TBL] [Abstract][Full Text] [Related]
18. Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
Brunnemer E; Wälscher J; Tenenbaum S; Hausmanns J; Schulze K; Seiter M; Heussel CP; Warth A; Herth FJF; Kreuter M
Respiration; 2018; 95(5):301-309. PubMed ID: 29490307
[TBL] [Abstract][Full Text] [Related]
19. Tolerability and safety of nintedanib in elderly patients with idiopathic pulmonary fibrosis.
Uchida Y; Ikeda S; Sekine A; Katano T; Tabata E; Oda T; Okuda R; Kitamura H; Baba T; Komatsu S; Ogura T
Respir Investig; 2021 Jan; 59(1):99-105. PubMed ID: 32891571
[TBL] [Abstract][Full Text] [Related]
20. Subgroup Analysis for Chinese Patients Included in the INPULSIS
Xu Z; Li H; Wen F; Bai C; Chen P; Fan F; Hu N; Stowasser S; Kang J
Adv Ther; 2019 Mar; 36(3):621-631. PubMed ID: 30729456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
